The ELEVATE Study shows that atogepant effectively prevents episodic migraine.

Published Date: 24 Apr 2023

Atogepant (Qulipta) performed better than a placebo in the ELEVATE study for preventing episodic migraine in patients who were resistant to other treatments.

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Oncologist on Hantavirus Cruise; Bile Duct Cancer Drug OK'd; Untreated Lung Cancers

2.

High Response Rate in Heavily Treated Multiple Myeloma With Novel Drug Combination

3.

Is a $2,000 Whole-Body MRI Worth It?

4.

Frontline Mosunetuzumab Shows High Response Rates in Follicular Lymphoma

5.

Vaccine elicits strong immune response in patients with pancreatic and colorectal cancer


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot